Skip to main content
. Author manuscript; available in PMC: 2015 Aug 13.
Published in final edited form as: Cancer Res. 2013 Nov 18;74(4):1153–1165. doi: 10.1158/0008-5472.CAN-13-0955

Figure 7. Prodigiosin inhibits tumor growth in vivo.

Figure 7

(A), SW480 xenografts and SW480 p73KD xenografts were treated with 5mg/kg prodigiosin, compound R or DMSO every 4 days for a total of three treatments. The mean tumor volume ± SEM before treatment and after treatment is shown (* P < 0.05 by unpaired t-test). (B), Image of three representative tumors from each group (SW480 xenografts and SW480 p73KD xenografts). (C), HT29 xenografts were treated with 5mg/kg prodigiosin and DMSO control for four times. The arrows show the days of the treatment. The mean tumor volume ± SEM is shown (* P < 0.05 by unpaired t-test). (D), Imaging of tumors from each group (HT29 xenografts). The tumors were excised at the end of the experiment (day 25 after inoculation). (E), H & E staining shows that prodigiosin treatment decreases tumor cell density in the whole tumor section and the invasive front of tumor. (F), Ki67 and TUNEL staining.